Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gentle brain ZAP help ALS patients breathe easier?

NCT ID NCT06719947

Symptom relief Sponsor: Universidade Federal do Rio Grande do Norte Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 4 times

Summary

This study is testing if a non-invasive brain stimulation method called HD-tDCS can help people with ALS. The goal is to see if it can improve muscle control and breathing by calming overactive brain cells. The study will involve 80 adults with ALS and will measure changes in brain activity and respiratory function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both sexes; diagnosis of ALS according to the revised El Escorial criteria; * Age between 18 and 80 years; * Forced Vital Capacity greater than 50% of predicted; * Sniff nasal inspiratory pressure greater than 40 cmH2O; * A telephone number to contact the care team and who signed the study consent form. Exclusion Criteria: * Subjects who are unable to understand or perform any of the study procedures; * Subjects who do not agree to participate or voluntarily request withdrawal from the study at any time; * Subjects with cardiac, respiratory, or musculoskeletal comorbidities; * Subjects using invasive mechanical ventilation; * Subjects with a tracheostomy; * Subjects with a pacemaker; * Subjects with metallic brain implants or other electronic implants; * Subjects with a cochlear implant; * Subjects with epileptic activity or a history of epilepsy, or a family history of epilepsy; * Subjects with a history of stroke or tumor; * Subjects prone to severe hemodynamic fluctuations, acute infectious processes, and/or inflammatory conditions; * Pregnant women at the time of recruitment; * Subjects who are unable to complete the intervention protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis (ALS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis central nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis (ALS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • PneumoCardioVascular Lab - HUOL/UFRN

    RECRUITING

    Natal, Rio Grande do Norte, 59010-090, Brazil

  • Universidad Autónoma de Chile

    NOT_YET_RECRUITING

    Santiago, Santiago Metropolitan, 7500912, Chile

  • Universidad do Chile

    NOT_YET_RECRUITING

    Santiago, Santiago Metropolitan, 8380453, Chile

  • Universidade de Brasília - Campus Ceilândia

    RECRUITING

    Brasília, Federal District, 72220-275, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.